Please login to the form below
tafamidis
This page shows the latest tafamidis news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
Vyndaqel (tafamidis meglumine) has been approved since 2011 for stage 1 polyneuropathy associated with ATTR, but the cardiomyopathy approval significantly extends the eligible patient population for the drug, already growing quickly
Latest news
-
Vyndaqel a bright spot as Pfizer comes under pressure
The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier
-
Pfizer buys dwarfism drug company Therachon for $810m
The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)
-
Speedy approval for Pfizer's Onpattro rival
Approved in two different formulations. Pfizer’s blockbuster-in-waiting drug tafamidis has gained FDA approval to treat cardiomyopathy in patients with rare disease ATTR. ... Pfizer filed the drug in two oral formulations, one known as Vyndaqel
-
Solid Q1 results lift Pfizer as it waits for pipeline boost
That will come on the back of product launches like tafamidis in rare disease transthyretin amyloid cardiomyopathy, a trio of recently-approved cancer drugs including Vizimpro (dacomitinib), a rival to
-
Alnylam gets EU nod for Onpattro amid pricing backlash
s Vyndaqel (tafamidis) has been registered in Europe since 2011 and costs in the region of $13, 000 per month. ... for tafamidis as a treatment for cardiomyopathy associated with hATTR amyloidosis after reporting positive results in the phase III
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... Standing in its way is a similarly priced antisense rival from
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
produced impressive data for its Vyndaqel (tafamidis). ... Onpattro looked to have the edge in terms of clinical data, but Pfizer has new data showing tafamidis is effective in treating patients with cardiomyopathy – the heart damage caused by the
-
Tough times for pharma in Portugal
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Neurofibromatosis: a condition that’s hard to say, but even harder to live with
- Do you know what PoTS is?
- St John & St Elizabeth Hospital “Putting people first” by Seven Stones
- OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
- Moderna’s chief exec expects to have COVID-19 vaccine data in November
- UK government invests in human challenge trials for COVID-19
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
- ...
- Can eLearning improve patient recruitment and retention?
- Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
- How Far Do You Want To Go?
- Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
Quick links
Infographics
